Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €55.02 EUR
Change Today +3.15 / 6.07%
Volume 76.1K
DBV On Other Exchanges
As of 9:12 AM 07/1/15 All times are local (Market data is delayed by at least 15 minutes).

dbv technologies sa (DBV) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/1/15 - €55.68
52 Week Low
08/11/14 - €18.27
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for DBV TECHNOLOGIES SA (DBV)

Related News

No related news articles were found.

dbv technologies sa (DBV) Related Businessweek News

No Related Businessweek News Found

dbv technologies sa (DBV) Details

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. The company provides Diallertest Milk, a diagnostic product for the detection of cow’s milk protein allergy (CMPA) in children. Its products include Viaskin Peanut, an immunotherapy product for the treatment peanut allergies in children, adolescents, and adults; Viaskin Milk for the treatment of CMPA and milk-induced eosinophilic esophagitis (EoE); and Viaskin Egg, a development program for the treatment of hen’s egg allergy. The company also develops other earlier stage product development programs, which comprise house dust mites allergy, EoE, pertusiss boost vaccine, and birch pollen allergy. DBV Technologies S.A. was founded in 2002 and is based in Bagneux, France.

56 Employees
Last Reported Date: 04/29/15
Founded in 2002

dbv technologies sa (DBV) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: €427.7K
Compensation as of Fiscal Year 2014.

dbv technologies sa (DBV) Key Developments

DBV Technologies Appoints Dr. Hugh Sampson as Chief Scientific Officer

DBV Technologies announced the appointment of Dr. Hugh Sampson as Chief Scientific Officer (CSO). In this new role and in partnership with Dr. Dupont, chairman of the company's Scientific Advisory Board, Dr. Sampson will lead DBV's research team, pursuing new Viaskin applications for the treatment of food allergies, while also supporting the Company's clinical development teams. Dr. Sampson's appointment as CSO will become effective on November 1, 2015. Dr. Sampson will also continue serving as an advisor to the company, as well as Director of the Research Center at the Jaffe Food Allergy Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Hugh A. Sampson, M.D., is a professor of Pediatrics at the Icahn School of Medicine at Mount Sinai School, N.Y., USA. He is Director of the Jaffe Food Allergy Institute; and Dean of Translational Biomedical Science at The Mount Sinai Medical Center.

DBV Technologies S.A. Announces Resignation of Peter Barton Hutt from the Board of Directors

On June 23, 2015, Mr. Peter Barton Hutt submitted his resignation from his position as a member of the board of directors of DBV Technologies S.A., ending his service as a non-employee director of the company effective June 23, 2015.

DBV Technologies Confirms Planned Initiation of Viaskin(R) Peanut Global Phase III Clinical Trial in Children Following End-of-Phase II Meeting with FDA and PIP Approval by EMA

DBV Technologies announced the completion of its End-of-Phase II meeting with the U.S. Food and Drug Administration. The outcome of this meeting on the clinical development plan for Viaskin Peanut is consistent with the previously announced positive opinion of the Paediatric Committee of the European Medicines Agency (EMA) on Viaskin Peanut's Paediatric Investigation Plan (PIP). Based on these regulatory consultations, DBV Technologies plans to initiate a global Phase III trial with Viaskin Peanut for the treatment of peanut allergic children 4 to 11 years of age in the fourth quarter of 2015. Based on these consultations, additional development plans for Viaskin Peanut in younger and older patients will be discussed with the FDA in the second half of 2015. In children 4-11 years of age, the anticipated Phase III trial, Peanut EPIT® Efficacy and Safety Study (PEPITES) is expected to begin in the fourth quarter of 2015 following the submission of the final clinical trial protocol and updated chemistry, manufacturing and controls information, and review by the FDA, as well as review and approval of Clinical Trial Applications in the other countries where the trial is expected to be conducted.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DBV:FP €55.02 EUR +3.15

DBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ALK-Abello A/S kr795.00 DKK +15.00
Allergy Therapeutics PLC 23.50 GBp +1.63
Merck & Co Inc $56.93 USD -0.36
Sanofi €89.80 EUR +1.56
Stallergenes SA €54.50 EUR -0.25
View Industry Companies

Industry Analysis


Industry Average

Valuation DBV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 171.7x
Price/Book 8.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 169.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DBV TECHNOLOGIES SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at